Pay in 4 interest-free payments of $5.78 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Semaglutide (Wegovy) was recommended by the National Institute for Health and Care Excellence (NICE) to treat thousands of people with obesity in England (March 2023)
There are, of course, less direct ways that investors can benefit from the GLP-1 rush as well
Studies show that GLP-1s decrease pain/stiffness, protect cartilage, and improve mobility, possibly preventing surgery for some
In a randomized trial of semaglutide 2.4 mg vs placebo for 1 year, 529 participants with HFpEF with a BMI of 30 kg/m2, there was a very large reduction in symptoms, improvement in exercise function in the GLP-1 drug assigned group
References Journal of Pharmacological Sciences Klicek R et al
US$ 20.38
US$ 20.99
US$ 22.02
US$ 29.37
